Revolution Medicines CFO sells 4,053 shares

Revolution Medicines’ CFO sold 4,053 RVMD shares under a Rule 10b5-1 plan to cover tax withholding from RSU vesting, retaining tens of thousands of RSUs.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that its Chief Financial Officer, Anders Jack, sold a total of 4,053 shares of common stock on September 16, 2026, in two open-market transactions at prices around $195–$199.30 per share. According to the company’s disclosure, these sales were executed under a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units. Following the transactions, the CFO’s holdings include 43,650 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 4,053 shares

Net Sell 2 txns

Insider Anders Jack

Role Chief Financial Officer

Sold 4,053 shs ($808K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	61	$195.00	$12K
Sale	Common Stock F1, F2	3,992	$199.3032	$796K

Holdings After Transaction: Common Stock — 119,216 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
2. F2. Includes 43,650 restricted stock units.

Key Figures

Shares sold (total): 4,053 shares Shares sold (first trade): 61 shares Shares sold (second trade): 3,992 shares +4 more

7 metrics

Shares sold (total) 4,053 shares Common stock sold by RVMD CFO on September 16, 2026

Shares sold (first trade) 61 shares Common stock sale on September 16, 2026 at $195.00 per share

Shares sold (second trade) 3,992 shares Common stock sale on September 16, 2026 at $199.3032 per share

Sale price (first trade) $195.00 per share 61 RVMD shares sold by CFO on September 16, 2026

Sale price (second trade) $199.3032 per share 3,992 RVMD shares sold by CFO on September 16, 2026

Restricted stock units held 43,650 RSUs RSUs included in CFO’s holdings after the reported transactions

Rule 10b5-1 plan adoption date May 31, 2023 Instruction letter governing the reported tax-withholding sales

Key Terms

Rule 10b5-1 instruction letter, restricted stock units, tax withholding obligation

3 terms

Rule 10b5-1 instruction letter regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023"

restricted stock units financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD disclose for its CFO?

Revolution Medicines disclosed that CFO Anders Jack sold a total of 4,053 shares of RVMD common stock on September 16, 2026 in two open-market transactions.

At what prices did the RVMD CFO sell shares on September 16, 2026?

The CFO sold 61 shares at $195.00 per share and 3,992 shares at $199.3032 per share of RVMD common stock on September 16, 2026.

Was the RVMD CFO’s share sale made under a Rule 10b5-1 plan?

Yes. The disclosure states the transactions were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, providing for pre-arranged trades.

Why did the RVMD CFO sell 4,053 shares?

The filing explains the sales were made to satisfy the reporting person’s tax withholding obligation arising from the vesting of restricted stock units, rather than as discretionary sales of investment holdings.

How many restricted stock units does the RVMD CFO still hold?

After the reported transactions, the CFO’s holdings include 43,650 restricted stock units, as disclosed in the footnotes.

Does the Form 4 show the RVMD CFO’s total common stock holdings after the sale?

No specific total common stock holdings after the sale are stated in the reported rows, but the filing notes that the CFO’s holdings include 43,650 RSUs following these transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:00 PM EDT Accepted by SEC EDGAR 09/18/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		61	D	$195	123,208	D
Common Stock	09/16/2026		S(1)		3,992	D	$199.3032	119,216(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

2. Includes 43,650 restricted stock units.

	/s/ Jack Anders	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)